Macquarimicin A inhibits membrane-bound neutral sphingomyelinase from rat brain.
Tanaka
M
M
Biomedical Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Nara
F
F
Yamasato
Y
Y
Masuda-Inoue
S
S
Doi-Yoshioka
H
H
Kumakura
S
S
Enokita
R
R
Ogita
T
T
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001409:Bacillus cereus / Q000187:drug effects / Q000201:enzymology; D001921:Brain / Q000187:drug effects / Q000201:enzymology*; D002351:Carrageenan; D015232:Dinoprostone / Q000096:biosynthesis; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D018942:Macrolides; D008847:Micromonospora / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000201:enzymology
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D018942:Macrolides; C094822:macquarimicin A; D002351:Carrageenan; D013108:Sphingomyelin Phosphodiesterase; D015232:Dinoprostone